Cell Cycle Regulation by Oncogenic Tyrosine Kinases in Myeloid Neoplasias: From Molecular Redox Mechanisms to Health Implications
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Neoplastic expansion of myeloid cells is associated with specific genetic changes that lead to chronic activation of signaling pathways, as well as altered metabolism. It has become increasingly evident that transformation relies on the interdependency of both events. Among the various genetic changes, the oncogenic BCR-ABL tyrosine kinase in patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) has been a focus of extensive research. Transformation by this oncogene is associated with elevated levels of intracellular reactive oxygen species (ROS). ROS have been implicated in processes that promote viability, cell growth, and regulation of other biological functions such as migration of cells or gene expression. Currently, the BCR-ABL inhibitor imatinib mesylate (Gleevec) is being used as a first-line therapy for the treatment of CML. However, BCR-ABL transformation is associated with genomic instability, and disease progression or resistance to imatinib can occur. Imatinib resistance is not known to cause or significantly alter signaling requirements in transformed cells. Elevated ROS are crucial for transformation, making them an ideal additional target for therapeutic intervention. The underlying mechanisms leading to elevated oxidative stress are reviewed, and signaling mechanisms that may serve as novel targeted approaches to overcome ROS-dependent cell growth are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 2×
“To date, (cid:6) 50 different point mutations encoding distinct single amino-acid substitutions in the BCR–ABL kinase domain have been identified in 50–90% of relapsed CML patients (38, 39, 126, 157, 332).”
Babior, B. M., Kipnes, R. S., & Curnutte, J. T. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107236 · Cited by 2,931
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502 · cited 1×
“…(such as VEGF and TGF-(cid:4) 3) (52, 107), erythropoiesis (such as erythropoietin and transferrin) (176, 301), cell proliferation and viability (such as p21, CDC25A, and BNIP3) (44, 56, 140), and energy metabolism (such as lactate dehydrogenase A and glucose trans-porter1 and 3) (105, 119) (Fig.”
Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes
Evans, J. L., Goldfine, I. D., Maddux, B. A., & Grodsky, G. M. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0039 · Cited by 2,232
Kobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224 · cited 1×
“The Nrf2-Keap1 complex recruits cullin family ubiquitin E3 ligases, preferably Cul3 (72, 190, 411), that functions to transfer activated ubiquitin to Nrf2, thus promoting poly-ubiquitination and proteasomal degradation.”
Huang, L. E., Gu, J., Schau, M., & Bunn, H. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7987 · Cited by 2,113
Jones, D. P. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.1865 · Cited by 1,726 · cited 1×
“178).”
Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress
Kops, G. J. P. L., Dansen, T. B., Polderman, P. E., Saarloos, I., Wirtz, K. W. A., Coffer, P. J., Huang, T.-T., Bos, J. L., Medema, R. H., & Burgering, B. M. T. (2002) · Nature · doi:10.1038/nature01036 · Cited by 1,580 · cited 1×
“FoxO proteins also activate a feedback loop in response to oxidative stress by inducing the expression of detoxifying enzymes such as Mn superoxide dismutase (194).”
FoxOs Are Critical Mediators of Hematopoietic Stem Cell Resistance to Physiologic Oxidative Stress
Tothova, Z., Kollipara, R., Huntly, B. J., Lee, B. H., Castrillon, D. H., Cullen, D. E., McDowell, E. P., Lazo-Kallanian, S., Williams, I. R., Sears, C., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.003 · Cited by 1,562 · cited 1×
“In mice, FoxO proteins are required for maintenance of the hematopoietic stem cell pool, and mice lacking FoxO were found to have elevated ROS and decreased expression of proteins regulating oxidative stress (371).”
Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells.
Schreck, R., Meier, B., Männel, D. N., Dröge, W., & Baeuerle, P. A. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.5.1181 · Cited by 1,508 · cited 1×
“B activation by IL-1, TNF, PMA, LPS, and H 2 O 2 in a number of human lymphocytic cells as well as a mouse fibroblast cell line (326).”
Zhang, D. D., & Hannink, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.22.8137-8151.2003 · Cited by 1,480 · cited 1×
“In addition to potentially retaining Nrf2 in the cytoplasm, Keap1 also targets Nrf2 for ubiquitination and subsequently proteasomal degradation (410).”
Cell transformation by the superoxide-generating oxidase Mox1
Suh, Y.-A., Arnold, R. S., Lassegue, B., Shi, J., Xu, X., Sorescu, D., Chung, A. B., Griendling, K. K., & Lambeth, J. D. (1999) · Nature · doi:10.1038/43459 · Cited by 1,480
Oxidative stress and cancer: Have we moved forward?
Halliwell, B. (2007) · Biochemical Journal · doi:10.1042/bj20061131 · Cited by 1,302
Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN
Tamura, M., Gu, J., Matsumoto, K., Aota, S.-I., Parsons, R., & Yamada, K. M. (1998) · Science · doi:10.1126/science.280.5369.1614 · Cited by 1,215
Jiang, B. H., Semenza, G. L., Bauer, C., & Marti, H. H. (1996) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1996.271.4.c1172 · Cited by 1,213
Ramos-Gomez, M., Kwak, M.-K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., & Kensler, T. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051618798 · Cited by 1,102
Trachootham, D., Zhou, Y., Zhang, H., Demizu, Y., Chen, Z., Pelicano, H., Chiao, P. J., Achanta, G., Arlinghaus, R. B., Liu, J., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.009 · Cited by 1,080
Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo
Meng, T.-C., Fukada, T., & Tonks, N. K. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00445-8 · Cited by 1,040
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
Cullinan, S. B., Gordan, J. D., Jin, J., Harper, J. W., & Diehl, J. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8477-8486.2004 · Cited by 986
Lee, S.-R., Kwon, K.-S., Kim, S.-R., & Rhee, S. G. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.25.15366 · Cited by 969
Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate
Salmeen, A., Andersen, J. N., Myers, M. P., Meng, T.-C., Hinks, J. A., Tonks, N. K., & Barford, D. (2003) · Nature · doi:10.1038/nature01680 · Cited by 951 · cited 1×
“…cysteine residue present in the phosphatase signature motif to a specific cysteine sulfenic acid intermediate, and this is rapidly converted to a cysteine sulfenyl–amide intermediate, resulting in a large conformational change in the active site accompanied by inhibition of substrate binding (311).”
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Jones, A. V. (2005) · Blood · doi:10.1182/blood-2005-03-1320 · Cited by 843 · cited 1×
“…leading to a V617F (Val617Phe) substitution in Jak2 has been reported in patients with polycythemia vera, essential thrombo-cythemia, idiopathic myelofibrosis, as well as in several myeloproliferative disorders, and infrequently in myelodysplastic syndromes (26, 172, 177, 197, 216, 350, 415).”
Lander, H. M., Tauras, J. M., Ogiste, J. S., Hori, O., Moss, R. A., & Schmidt, A. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.28.17810 · Cited by 813
Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression
Neumann, C. A., Krause, D. S., Carman, C. V., Das, S., Dubey, D. P., Abraham, J. L., Bronson, R. T., Fujiwara, Y., Orkin, S. H., & Van Etten, R. A. (2003) · Nature · doi:10.1038/nature01819 · Cited by 801 · cited 1×
“Prdx1-deficient fibroblasts show decreased proliferation and increased sensitivity to oxidative DNA damage, ultimately implicating Prdx1 as an important defense against oxidants in aging mice (259).”
FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK
Essers, M. A., Weijzen, S., de Vries‐Smits, A. M., Saarloos, I., de Ruiter, N. D., Bos, J. L., & Burgering, B. M. T. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600476 · Cited by 798 · cited 1×
“Among the Fox family members (FoxA–FoxS), the FoxO proteins and their orthologues have been implicated in the oxidative stress response and may also serve to regulate longevity (94, 146, 267, 388).”
Enomoto, A. (2001) · Toxicological Sciences · doi:10.1093/toxsci/59.1.169 · Cited by 728
Redox signaling: hydrogen peroxide as intracellular messenger
Rhee, S. G. (1999) · Experimental & Molecular Medicine · doi:10.1038/emm.1999.9 · Cited by 701 · cited 1×
“Though ROS are notorious for their deleterious effects on disruption of membrane integrity and DNA damage, literature supporting a cell proliferative role of ROS at low thresholds is available (299).”
Elchuri, S., Oberley, T. D., Qi, W., Eisenstein, R. S., Jackson Roberts, L., Van Remmen, H., Epstein, C. J., & Huang, T.-T. (2005) · Oncogene · doi:10.1038/sj.onc.1208207 · Cited by 667 · cited 1×
“For example, mice with disruption of the CuZn-SOD gene have an increased rate of liver cancer (91).”
Caniggia, I., Mostachfi, H., Winter, J., Gassmann, M., Lye, S. J., Kuliszewski, M., & Post, M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8316 · Cited by 644
Hemoprotein Bach1 regulates enhancer availability of heme oxygenase‐1 gene
Sun, J., Hoshino, H., Takaku, K., Nakajima, O., Muto, A., Suzuki, H., Tashiro, S., Takahashi, S., Shibahara, S., Alam, J., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf516 · Cited by 637 · cited 2×
“In conjunction with a small Maf protein, Bach1 acts as a transcriptional repressor and binds to ARE, thus quenching the target gene expression and opposing the function and gene expression of the Nrf2 transactivator (271, 353).”
Copland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L. (2006) · Blood · doi:10.1182/blood-2005-07-2947 · Cited by 635 · cited 1×
“CD38-leukemic “stem cells” that are thought to be the source of cells that can lead to hematologic relapse due to new mutations (70).”
Skorski, T., Bellacosa, A., Nieborowska‐Skorska, M., Majewski, M., Martinez, R., Choi, J. K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T. O., et al. (1997) · The EMBO Journal · doi:10.1093/emboj/16.20.6151 · Cited by 567 · cited 2×
“The PI3K/Akt pathway has already been shown to be crucial for transformation by BCR–ABL (340, 341) as well as other oncoproteins,”
Ivan, M., Haberberger, T., Gervasi, D. C., Michelson, K. S., Günzler, V., Kondo, K., Yang, H., Sorokina, I., Conaway, R. C., Conaway, J. W., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192342099 · Cited by 561 · cited 1×
“…that chemical inhibitors blocking the activity of prolyl hydroxylases, such as iron chelators, or dimethyloxallyl glycine, which competes with 2-oxoglutarate for binding at the hydroxylase, prevent HIF proline hydroxylation, causing accumulation, and hence stabilization of HIF-1 (cid:2) (169).”
Ambasta, R. K., Kumar, P., Griendling, K. K., Schmidt, H. H. H. W., Busse, R., & Brandes, R. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406486200 · Cited by 541
HIF-Dependent Antitumorigenic Effect of Antioxidants In Vivo
Gao, P., Zhang, H., Dinavahi, R., Li, F., Xiang, Y., Raman, V., Bhujwalla, Z. M., Felsher, D. W., Cheng, L., Pevsner, J., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.004 · Cited by 523
Takada, Y., Mukhopadhyay, A., Kundu, G. C., Mahabeleshwar, G. H., Singh, S., & Aggarwal, B. B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212389200 · Cited by 495
CHANAS, S. A., JIANG, Q., McMAHON, M., McWALTER, G. K., McLELLAN, L. I., ELCOMBE, C. R., HENDERSON, C. J., WOLF, C. R., MOFFAT, G. J., ITOH, K., et al. (2002) · Biochemical Journal · doi:10.1042/bj20020320 · Cited by 460 · cited 1×
“On the other hand, mice with Nrf2 gene disruption are more sensitive to some chemical compounds, and Nrf2 is required for detoxification that involves expression of (cid:5) -glutamylcysteine synthase, glutathione S-transferase, and NADPH quinone oxidoreductase (60, 62, 93, 167, 201, 293).”
Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1
Rolfs, A., Kvietikova, I., Gassmann, M., & Wenger, R. H. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.32.20055 · Cited by 401
Nowicki, M. O., Falinski, R., Koptyra, M., Slupianek, A., Stoklosa, T., Gloc, E., Nieborowska-Skorska, M., Blasiak, J., & Skorski, T. (2004) · Blood · doi:10.1182/blood-2004-05-1941 · Cited by 278
Characterization of RAC3, a Novel Member of the Rho Family
Haataja, L., Groffen, J., & Heisterkamp, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.33.20384 · Cited by 243 · cited 1×
“The family of Rac proteins includes three highly homologous members that are ubiquitously expressed, with the exception of Rac2, which seems more restricted to hematopoietic cells (134, 252, 336).”
BRCA1 Induces Antioxidant Gene Expression and Resistance to Oxidative Stress
Bae, I., Fan, S., Meng, Q., Rih, J. K., Kim, H. J., Kang, H. J., Xu, J., Goldberg, I. D., Jaiswal, A. K., & Rosen, E. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1119 · Cited by 222
Redox regulation of the hypoxia-inducible factor
Pouysségur, J., & Mechta-Grigoriou, F. (2006) · Biological Chemistry · doi:10.1515/bc.2006.167 · Cited by 186 · cited 1×
“A number of groups have previously reported increased levels of ROS under hypoxic conditions, however others have reported the reverse (63, 286).”
Thomas, E. K., Cancelas, J. A., Chae, H.-D., Cox, A. D., Keller, P. J., Perrotti, D., Neviani, P., Druker, B. J., Setchell, K. D. R., Zheng, Y., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.015 · Cited by 147 · cited 1×
“In murine models with Rac1 and Rac2 gene disruption, the combination of both proteins has been shown to be required for BCR–ABL-mediated transformation (366).”
BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint
Dierov, J., Dierova, R., & Carroll, M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00056-x · Cited by 117
Cited by
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
Oxidative Stress and Lipid Peroxidation Products in Cancer Progression and Therapy
Barrera, G. (2012) · ISRN Oncology · doi:10.5402/2012/137289 · Cited by 820
Redox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities
Wondrak, G. T. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2541 · Cited by 462
Chronic myeloid leukemia: mechanisms of blastic transformation
Perrotti, D., Jamieson, C., Goldman, J., & Skorski, T. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41246 · Cited by 397
Do reactive oxygen species play a role in myeloid leukemias?
Hole, P. S., Darley, R. L., & Tonks, A. (2011) · Blood · doi:10.1182/blood-2011-01-326025 · Cited by 254
Metadata
- Authors
- Rodrigues, M. S., Reddy, M. M., & Sattler, M.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2008-10
- Volume
- 10
- Issue
- 10
- Pages
- 1813-1848
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W2083500049
- Cited by
- 57
- References
- 47
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.